brand of recombinant C1-inhibitor (conestat alpha). Ruconest® is approved by FDA and EMA and is delivered intravenously. Ruconest® is approved for self-administration.
Company: Pharming Group NV
The HAEi Global Access Program enables patients to gain access to Ruconest®–through an ethical and regulatory compliant “Named Patient Program” mechanism–in all countries where the drug is not commercially available.
Global Access Programs provide biopharmaceutical companies with a way to allow ethical access to their pre-license/unlicensed medicines to help patients with unmet medical needs. Access is provided in response to physician requests, in a fully compliant manner, where no alternative treatment options are available.
How can I get access to Ruconest®?
If you would like to learn more about the Ruconest® through the HAEi Global Access Program, please discuss with your treating physician who should then get in touch with HAEi.
Physician enquiries regarding Ruconest® should be directed by email to: firstname.lastname@example.org.
Please note that we cannot handle direct patient inquiries.